Carbidopa/levodopa (Dizlin Pharmaceuticals)

卡比多巴/左旋多巴 (Dizlin Pharmaceuticals)

Report date: 2025/04/20 20:00:03

Base Information

Drug NameCarbidopa/levodopa (Dizlin Pharmaceuticals)
Drug Alias NameInfudopa SubCInfudopa IntraVDIZ-102DIZ-101
ClassificationSmall molecules
Mechanisms of ActionDOPA decarboxylase inhibitorsDopamine receptors agonists
TargetsAromatic-L-amino-acid decarboxylaseDopamine receptors
Therapy Area/IndicationsParkinson Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySweden
CombinationsYes
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesDizlin Pharmaceuticals AB
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesDizlin Pharmaceuticals ABNeuraxpharm Group
Active IndicationsN/A
Inactive IndicationsParkinson Disease

Other Information

ATC CodeN/A
Related LinksN/A